Trial Profile
Double-blind, placebo-controlled, crossover study evaluating changes in energy balance during Dapagliflozin therapy in Type 2 Diabetes—The Energize Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 22 Jul 2018 New trial record
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association